Ardissino D, Savonitto S, Egstrup K, Rasmussen K, Bae E A, Omland T, Schjelderup-Mathiesen P M, Marraccini P, Merlini P A, Wahlqvist I
Divisione di Cardiologia, IRCCS, Policlinico S. Matteo, Pavia, Italy.
J Am Coll Cardiol. 1995 Jun;25(7):1516-21. doi: 10.1016/0735-1097(95)00042-3.
The present study was designed to investigate which characteristics of anginal symptoms or exercise test results could predict the favorable anti-ischemic effect of the beta-adrenergic blocking agent metoprolol and the calcium antagonist nifedipine in patients with stable angina pectoris.
The characteristics of anginal symptoms and the results of exercise testing are considered of great importance for selecting medical treatment in patients with chronic stable angina pectoris. However, little information is available on how this first evaluation may be used to select the best pharmacologic approach in individual patients.
In this prospective multicenter study, 280 patients with stable angina pectoris were enrolled in 25 European centers. After baseline evaluation, consisting of an exercise test and a questionnaire investigating patients' anginal symptoms, the patients were randomly allocated to double-blind treatment for 6 weeks with either metoprolol (Controlled Release, 200 mg once daily) or nifedipine (Retard, 20 mg twice daily) according to a parallel group design. At the end of this period, exercise tests were repeated 1 to 4 h after drug intake.
Both metoprolol and nifedipine prolonged exercise tolerance over baseline levels; the improvement was greater in the patients receiving metoprolol (p < 0.05). Multivariate analysis revealed that low exercise tolerance was the only variable associated with a more favorable effect within each treatment group. Metoprolol was more effective than nifedipine in patients with a lower exercise tolerance or with a higher rate-pressure product at rest and at ischemic threshold. None of the characteristics of anginal symptoms or exercise test results predicted a greater efficacy of nifedipine over metoprolol.
The results of a baseline exercise test, but not the characteristics of anginal symptoms, may offer useful information for selecting medical treatment in stable angina pectoris.
本研究旨在调查心绞痛症状或运动试验结果的哪些特征能够预测β-肾上腺素能阻滞剂美托洛尔和钙拮抗剂硝苯地平对稳定型心绞痛患者的良好抗缺血作用。
心绞痛症状特征和运动试验结果对于慢性稳定型心绞痛患者的药物治疗选择至关重要。然而,关于如何利用这一初步评估为个体患者选择最佳药物治疗方法的信息却很少。
在这项前瞻性多中心研究中,25个欧洲中心招募了280例稳定型心绞痛患者。在进行包括运动试验和调查患者心绞痛症状的问卷在内的基线评估后,根据平行组设计,患者被随机分配接受为期6周的双盲治疗,分别服用美托洛尔(缓释片,每日一次,200毫克)或硝苯地平(缓释片,每日两次,20毫克)。在此期间结束时,在服药后1至4小时重复进行运动试验。
美托洛尔和硝苯地平均使运动耐量延长超过基线水平;接受美托洛尔治疗的患者改善更大(p<0.05)。多变量分析显示,低运动耐量是每个治疗组中与更有利效果相关的唯一变量。在运动耐量较低或静息及缺血阈值时心率-血压乘积较高的患者中,美托洛尔比硝苯地平更有效。心绞痛症状或运动试验结果的任何特征均未预测硝苯地平比美托洛尔有更大疗效。
基线运动试验结果而非心绞痛症状特征可为稳定型心绞痛的药物治疗选择提供有用信息。